BridgeBio Pharma, Inc. Common Stock (BBIO) Stock Price

BBIOStock

$66.39+20.64%52W

Market Cap$12.98B

P/E—

PEG Ratio—

Div yield—

Beta0.95

BBIO Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-24.71%

Price vs S&P 500 (4W)1.04%

VGM Score58.39

Book Value / Share (Quarterly)$0.47

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)86.30%

Cash Flow / Share (Quarterly)$-2.24

Price vs S&P 500 (YTD)-25.13%

Gross Margin (TTM)94.44%

Net Profit Margin (TTM)-97.03%

EPS (TTM)$-3.57

10-Day Avg Trading Volume2.50M

EPS Excl Extra (TTM)$-3.57

Revenue Growth (5Y)127.44%

EPS (Annual)$-3.79

ROI (Annual)-83.58%

Gross Margin (Annual)95.82%

Net Profit Margin (5Y Avg)-1745.26%

Cash / Share (Quarterly)$3.69

Revenue Growth QoQ (YoY)120.39%

ROA (Last FY)-77.45%

Revenue Growth TTM (YoY)202.39%

EBITD / Share (TTM)$-2.54

Operating Margin (TTM)-69.81%

Cash Flow / Share (Annual)$-2.34

P/B Ratio224.16x

P/B Ratio (Quarterly)150.71x

Net Income / Employee (Annual)$-869,200

EV / Revenue (TTM)21.96x

Net Interest Coverage (TTM)-2.17x

ROA (TTM)-61.19%

EPS Incl Extra (Annual)$-3.79

Current Ratio (Annual)2.77x

Quick Ratio (Quarterly)1.09x

3-Month Avg Trading Volume3.00M

52-Week Price Return20.64%

Revenue / Employee (TTM)$855,000

Tangible BV / Share (Quarterly)$-7.09

P/S Ratio (Annual)25.85x

Asset Turnover (Annual)0.54x

52-Week High$93.42

Operating Margin (5Y Avg)-1664.55%

EPS Excl Extra (Annual)$-3.79

CapEx CAGR (5Y)4.99%

26-Week Price Return-14.81%

Quick Ratio (Annual)2.53x

13-Week Price Return-18.42%

Total Debt / Equity (Annual)8.27x

Current Ratio (Quarterly)1.23x

Enterprise Value$15.66B

Revenue / Share Growth (5Y)106.45%

Asset Turnover (TTM)0.63x

Revenue / Employee (Annual)$602,000

Pretax Margin (Annual)-145.89%

Cash / Share (Annual)$3.02

3-Month Return Std Dev30.32%

Gross Margin (5Y Avg)91.77%

Net Income / Employee (TTM)$-829,600

ROE (Last FY)-774.99%

Net Interest Coverage (Annual)-1.88x

EPS Basic Excl Extra (Annual)$-3.79

Receivables Turnover (TTM)4.30x

Total Debt / Equity (Quarterly)8.27x

EPS Incl Extra (TTM)$-3.57

ROI (TTM)-65.34%

P/S Ratio (TTM)18.20x

Pretax Margin (5Y Avg)-1775.49%

Revenue / Share (Annual)$2.62

Tangible BV / Share (Annual)$-8.52

Price vs S&P 500 (52W)5.11%

Year-to-Date Return-13.20%

5-Day Price Return0.97%

EPS Normalized (Annual)$-3.79

ROA (5Y Avg)-77.25%

Net Profit Margin (Annual)-144.39%

Month-to-Date Return0.90%

Cash Flow / Share (TTM)$-3.94

EBITD / Share (Annual)$-2.81

Operating Margin (Annual)-108.46%

LT Debt / Equity (Annual)8.22x

ROI (5Y Avg)-78.45%

LT Debt / Equity (Quarterly)8.22x

EPS Basic Excl Extra (TTM)$-3.57

P/B Ratio (Annual)150.71x

Inventory Turnover (TTM)1.12x

Pretax Margin (TTM)-98.68%

Book Value / Share (Annual)$0.47

Price vs S&P 500 (13W)-21.11%

Beta0.95x

Revenue / Share (TTM)$3.64

ROE (TTM)-206.74%

52-Week Low$52.75

vGradeF

gGradeA

mGradeB

vgmGradeC

BBIO Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 10, 2026	-$0.58	-$0.78	-33.87%(-$0.20)
Q1 2026	May 7, 2026	-$0.62	-$0.84	-36.22%(-$0.22)
Q4 2025	Feb 24, 2026	-$0.62	-$0.94	-50.63%(-$0.32)
Q3 2025	Oct 29, 2025	-$0.78	-$0.72	+7.73%(+$0.06)
Q2 2025	Aug 5, 2025	-$0.60	-$0.95	-57.12%(-$0.35)

BBIO Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.21

4.20

4.11

4.10

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78
MIRMMirum Pharmaceuticals, Inc. Common Stock	F	B	C	8.4x	44.0%	81.7%	—	$80.14

About BridgeBio Pharma, Inc. Common Stock

BridgeBio Pharma develops treatments for genetic diseases through a late-stage pipeline of four programs targeting Mendelian disorders, oncology, and gene therapy. Its lead candidate, Attruby (acoramidis), is an orally administered small molecule designed to stabilize transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

BBIO Next Earnings Report

Report dateOct 28, 2026

QuarterQ3 2026

Report timeAMC

EPS estimate-$0.58

Revenue estimate$282.69M

Also reporting on Oct 28, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for October 2026

BBIO Insider Transactions

SellSep 17, 2026
KUMAR NEIL
Chief Executive Officer
Shares: 10,000Value: $690,847
SellAug 19, 2026
KUMAR NEIL
Chief Executive Officer
Shares: 44,980Value: $3.73M
SellJul 30, 2026
APULI MARICEL
Officer
Shares: 2,000Value: $160,120

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for September 2026

Companies in Related Industries

DDDuPont de Nemours, Inc. Common StockPlastics & Resins
EXELExelixis IncBiological Products
HALOHalozyme Therapeutics, Inc.Biological Products
NBIXNeurocrine Biosciences IncBiological Products
RPMRPM International, Inc.Paints & Coatings
TECHBio-Techne Corp.Biological Products
ALBAlbemarle CorporationPlastics & Resins
RGENRepligen CorpBiological Products

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.1

Buy

Consensus rating

52-Week Range

Low$52.75

High$93.42